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Microbeam radiation therapy (MRT) is a new form of preclinical radiotherapy using quasi-parallel arrays
of synchrotron X-ray microbeams. While the deposition of several hundred Grays in the microbeam
paths, the normal brain tissues presents a high tolerance which is accompanied by the permanence of
apparently normal vessels. Conversely, the efﬁciency of MRT on tumor growth control is thought to be
related to a preferential damaging of tumor blood vessels.
The high resistance of the healthy vascular network was demonstrated in different animal models by
in vivo biphoton microscopy, magnetic resonance imaging, and histological studies. While a transient
increase in permeability was shown, the structure of the vessels remained intact. The use of a chick
chorioallantoic membrane at different stages of development showed that the damages induced by
microbeams depend on vessel maturation. In vivo and ultrastructural observations showed negligible
effects of microbeams on the mature vasculature at late stages of development; nevertheless a complete
destruction of the immature capillary plexus was found in the microbeam paths. The use of MRT in
rodent models revealed a preferential effect on tumor vessels. Although no major modiﬁcation was
observed in the vasculature of normal brain tissue, tumors showed a denudation of capillaries accom-
panied by transient increased permeability followed by reduced tumor perfusion and ﬁnally, a decrease
in number of tumor vessels. Thus, MRT is a very promising treatment strategy with pronounced tumor
control effects most likely based on the anti-vascular effects of MRT.
© 2015 Published by Elsevier Ltd on behalf of Associazione Italiana di Fisica Medica. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Background
Since the 1990s, microbeam radiation therapy (MRT) has been
proposed and developed as a new form of preclinical radiotherapy
[1e6]. MRT, invented at the National Synchrotron Light Source
(NSLS) of Brookhaven National Laboratory (BNL), Upton, New York,
uses highly collimated, quasi-parallel arrays of X-ray microbeams
with an energy of 50e600 keV. This can now be produced by third
generation synchrotron sources such as the European Synchrotron
Radiation Facility (ESRF), in Grenoble, France. The effects of mi-
crobeams derived from synchrotron X-rays was ﬁrst studied in
cerebral tissues, where arrays of microplanar beamlets safelyBouchet).
alf of Associazione Italiana di Fisidelivered radiation doses to normal animal brains that were much
higher than maximum doses tolerated by the brain of animals or
patients from any standard millimeter-wide radiosurgical beam
[3,5]. This unusually high normal tissue tolerancewas accompanied
by the permanence of apparently normal vessels in the path of the
microbeams, with preserved endothelial nuclei, while neuronal
and astrocyte nuclei had disappeared [3]. This resistance of normal
vascular tissue was viewed as a central feature for the rationale of
planning the use of MRT for brain tumors [5]. Studies performed
over the past decades have proved the therapeutic efﬁciency of
MRT for different types of tumors. Further, the tolerance of normal
tissues to this type of irradiation has been characterized in several
animal models. Uni- or bidirectional MRT reduced or even stopped
the growth of tumors such as the EMT6 murine mammary carci-
noma [7], an aggressive mouse model of squamous cell carcinoma
[8], and of 9L intracerebral gliosarcoma in rats [3,9e12]. The
tolerance of normal tissues to microbeam irradiation (MBI) wasca Medica. This is an open access article under the CC BY-NC-ND license (http://
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such as the duck brain in ovo [14], the chick chorioallantoic mem-
brane (CAM) [15] and, the in vivo cerebella of normal, suckling
SpragueeDawley rat pups [16], as well as adult rat and mouse
brains [3,5,17,18] and in normal weanling piglet cerebella [19,20]
(Fig. 1A). Normal tissues, even when developing, were deemed to
be about 10 times more tolerant of microbeam irradiation than
conventional, broad beam (BB), exposure. For instance, an 11 mm
wide microbeam irradiation of the spinal cord did not induce any
paralysis for entrance doses up to 500 Gy while all the rats exposed
to entrance doses >150 Gy delivered by a 1.3 mmwide single beam
rapidly developed paralysis [21]. An example of a histological sec-
tion of the hindbrain of a weaned piglet is shown in Fig. 1A. Mi-
crobeams can selectively ablate neurons, oligodendrocytes and
astrocytes in the central nervous system in their path, without
causing tissue necrosis. This surprising tolerance of normal brain
tissue might be a consequence of the radioresistance of normal
brain vasculature. Conversely, it has been proposed that the efﬁ-
ciency of MRT on tumor growth control is related to a preferential
damaging of tumor vessels.
During the last ten years, the response of normal and tumor
vessels to spatially fractionated high dose exposures has been
studied extensively. In the present report we attempt to present a
summary of the current knowledge and progress in this area.
Normal vessel response to microbeam radiation
When applied to the brain of rodents, microbeam irradiation
does not modify any of the numerous structural or functional pa-
rameters such as blood volume, vascular density and perfusion,
even after delivery of doses up to 1000 Gy [17,18]. The endothelial
cell lining of the vessels in the microbeam paths remains intact,
whatever the delay of observation (from a few hours up to 1 month
after irradiation by microbeams (Fig. 1B)); no denudation of the
vascular basement membrane, no hemorrhages, no thrombi have
been observed. A transient diffusion of sulforhodamine B (SRB,
0.58 kDa) was observed by intravital two photon microscopy in
microbeam irradiated regions from 12 h until 12 days after irradi-
ation, but only for a high dose exposure (1000 Gy), not for a
moderate dose (312 Gy) [17]. The perivascular deposition of SRB has
been observed within the microbeams path but not in the sur-
rounding tissue, indicating that irradiation by microbeamsFigure 1. A- Histological section of a piglet cerebellum 15 months after irradiation with an
conﬁned to the microbeam's paths. No macroscopic necrosis was detected in irradiated norm
photon microscopy of a mouse vascular network 7 days after MRT, with an entrance dose o
intravascular injection of ﬂuorescein isothiocyanate-dextran (FITC, green, 70kD) revealed tra
dextran of low molecular size (0.58 kD) labeled with sulforhodamine B (SRB, red) within t
dextran (70 kD). Adapted from Serduc et al. 2006 [17]. (For interpretation of the referencesenhances the vascular permeability. Brain edema, usually observed
after conventional radiotherapy, is considerably reduced after MRT.
Edema of a mixed, i.e. vasogenic and cellular, type has been
observed using magnetic resonance (MR) diffusion tensor imaging
at an early stage (12 h) after exposure to very high peak entrance
dose (1000 Gy), while a moderate and clinically relevant micro-
beam irradiation (e.g., 312 Gy) only induced a short and transient
cellular edema, but no blood brain barrier breakdown (BBBB) [18].
These results have been conﬁrmed by water content measurement
in brain tissues [18]. Indeed, there was an increase in cerebral water
content (CWC) the ﬁrst week after exposure, while no BBBB and no
changes in brain vessel permeability nor in CWC were measured
after exposure to a lower dose of 312 Gy.
Whatever the dose delivered, brain vessels remained perfused
and no changes in animal behavior were observed [20]. These re-
sults are concordant with those described by Dilmanian et al.
(2003) [22], who showed that the BBBB for albumin-FITC took place
in only 9L gliosarcoma tumor vessels, which were not permeable
before MRT, and not in capillaries in normal brain tissue after MBI
(entrance dose 800 Gy, microplanar width 27 mm, microplanar
spacing 200 mm) [22]. Brain vessel vulnerability to irradiation has
been shown to change with: 1) radiation dose (see above); 2)
microbeam width; and 3) vessel size. In 2009, Serduc et al.
demonstrated that at constant valley doses (dose received between
the microbeam paths), high radiation peak entrance doses
(860 Gy), delivered to the head of rats by two cross-ﬁred arrays of
thin microbeams (25 mm), were more neurotoxic than lower doses
(480 Gy) deposited by arrays of 50 mm wide microbeams. Indeed,
normal rats, exposed to such a hemi-cranial brain irradiation by
two cross-ﬁred arrays of 25 mm or 50 mmwide beamlets, but to the
same valley dose, survived 4.5 days (median survival time, MST), or
68 days after MBI, respectively [23]. However, when themicrobeam
widths were increased up to 75 mm and the radiation peak entrance
dose reduced to 320 Gy, MST of rats decreased to 48 days. This
demonstrated that the brain vascular network can tolerate 50 mm
wide lesions induced by microbeams, but not with peak doses
exceeding 500 Gy. This is important when minibeam radiation
therapy, i.e., using beamlets with a size range of >100e900 mm, is
applied to brain tissues using hectogray doses. However, until now,
no work has been published on the tolerance of normal brain
vessels to suchwide beams. Preliminary unpublished data obtained
in INSERM U836 laboratories tend to show that irradiation byarray of 25 mm wide microbeams and an entrance dose of 300 Gy. Cellular damage is
al brains of rodents and piglets. Adapted from Laissue et al. 2001 [20]. B- Intravital two
f 1000 Gy, and microbeam width of 25 mm. The perfused blood vessels, visualized by
nsiently increased vessel permeability as demonstrated by a perivascular deposition of
he microbeams path (large arrow). There was no extravasation of ﬂuorescein-labeled
to color in this ﬁgure legend, the reader is referred to the web version of this article.)
A. Bouchet et al. / Physica Medica 31 (2015) 634e641636beamlets wider than 100 mm provokes vessel responses that are in
marked contrast with the quick repair observed after irradiation by
thin microbeams. For example, 200 mm wide beams induced
macroscopic brain necrosis due to angionecrosis, beginning 3
weeks after exposure to an entrance dose of 400 Gy. Studies of the
inﬂuence of beam size and dose on brain vessels are currently in
progress, but need further expansion to determine whether the
demonstrated vessel resistance to MBI also occurs after exposure to
minibeams. Finally, large vessels display an extraordinary tolerance
to MBI at least in skeletal muscles. Van der Sanden et al. irradiated
saphenous arteries in the lower limbs of mice with peak entrance
doses up to 1000 Gy, delivered by an array of 50 mm wide micro-
beams spaced 400 mm on center [24]. The microscopically narrow
arterial smooth muscle cell layer segments in the microplanar
beam paths became atrophic and ﬁbrotic in a dose-dependent
pattern. The wide tunica media segments sited between those
paths hypertrophied but the arteries remained patent and
perfused, as observed in situ by two-photon microscopy, as well as
histopathologically. Comparable doses delivered by un-segmented
broad beams destroy normal arteries [25]. This vascular tolerance is
instrumental in maintaining vascular oxygen and nutrient supply
and is a major advantage of MRT. The tolerance relates to the highFigure 2. Intravital microscopy of CAMs (a and b), vascular parameter quantiﬁcation (c and
(eei). CAM8 (a) and CAM12 (b) are shown after injection of FITC-dextran (2000 kDa, Sigm
CAM8, microbeam peak doses of 200 Gy induced extensive lesions of the capillary plexus,
(arrowheads) in the beam path. Many of the arterioles and venules collapsed. The larger ve
small arteries (arrows), nearly parallel to the beams. (b) Six hours after exposure to 300 Gy
where the capillary plexus was cut by an array of tiny, unperfused dark stripes correspondin
affected (arrowheads). (c) Relative numerical density of preserved microvessels (diameter <
based on images from semi-thin sections. The microvessel density in the controls (white colu
deviations (*, p < 0.05). (d) Fractions of unperfused microvascular areas in CAM8 and CAM
obtained in vivo. Mean values (n ¼ 4) and standard deviations (**, p < 0.001) are given.therapeutic ratio of MRT for solid tumors in rodent brains. The
stability of the normal vasculature exposed to MRT is in marked
contrast to the changes that occur after conventional radiotherapy.
Microbeam radiation-induced damage depends on the
vascular maturation stage
The differential effect of microbeams on mature and immature
vessels was also illustrated by in vivo and morphometric observa-
tions of a chick chorioallantoic membrane (CAM)model at different
stages of development. A CAM is an almost pure avian vascular
system in which immature vessels, lacking periendothelial
coverage, mature within few days to vessels with such coverage
[15]. CAMs cultivated in Petri dishes were irradiated with micro-
planar beams (width, ~25 mm; interbeam spacing, ~200 mm) at
entrance doses of 200 Gy. The in vivomonitoring of immature CAM
vasculature over 8 days of development (CAM8) revealed a near
total destruction of the immature capillary plexus 6 h after MBI
with 200 Gy (Fig. 2a). Large areas were no longer perfused 6 h after
irradiation. Some solitary capillaries sited in the path between the
beams were partially preserved, with intact supplying vessels
running parallel between the beams. Small arterioles and veinsd) and CAM morphology 6 h after exposure to microbeams with a peak dose of 200 Gy
a) scale bar: 100 mm. The on-center spacing of the microbeam paths is 200 mm. (a) In
identiﬁed as large unperfused areas (asterisks), and destroyed small supplying vessels
ssels appear unaffected. Small capillary areas remained occasionally perfused only by
microbeam peak doses, the effects in the CAM12 were limited to the microvasculature,
g to the path of microbeams (double arrows). Few small supplying vessels were mildly
50 mm) in CAM8 and CAM12, 6 h after a peak dose of 200 Gy (black columns) is shown,
mns) was taken as reference and equal 1. Mean values (n ¼ 3) are shownwith standard
12 at 6 h after peak doses of 200 Gy are shown as measured in microscopy images
A. Bouchet et al. / Physica Medica 31 (2015) 634e641 637were collapsed or destroyed in the beam path, while larger arteries
and veins were not affected by the irradiation.
Conversely, 200 Gy MBI slightly affected CAM mature micro-
vasculature at 12 days of development (CAM12); negligible effects
on the vasculature were observed. Relative numerical density of
preserved microvessels 6 h after 200 Gy MBI was signiﬁcantly
(p < 0.05) higher in CAM12 than in CAM8 (Fig. 2c). In addition to
this, the fraction of unperfused microvascular areas was signiﬁ-
cantly (p < 0.001) lower in CAM12 than in CAM8 (Fig. 2d) 6 h after
200 Gy MBI. Even when the dose was increased to 300 Gy
(Fig. 2b), the CAM12 capillary plexus was less damaged than that
of CAM8 irradiated with a dose of 200 Gy. Infact, in CAM12 the
capillary vessels revealed only tiny, sharply demarcated, unper-
fused stripes along the beam path 6 h after exposure to 300 Gy
(Fig. 2b). Small supplying vessels were barely affected. The CAM
vasculature recovered rapidly and only small defects were
detectable in the capillary plexus 24 h after 300 Gy MBI. The
vascular pattern appeared similar to that of the non-irradiated
CAMs [15]. Microscopic and ultrastructural observations showed
a destruction of the plexus of immature capillaries in the irradi-
ated zone while the capillaries were preserved in between
(Fig. 3aee).
This comparison of MBI effects on different maturation stages of
the avian vessel network has clearly shown that vascular toxicity
and physiological effects of microbeam radiation depend on the
stage of capillary maturation. The time- and dose-dependent MBI-
induced vascular changes in CAMs differ markedly from those seen
in adult mice. It is not surprising that CAM vasculature, a transient,
developmental organ, should be more vulnerable to this type ofFigure 3. (a) Overview of CAM8 (semi-thin section) shows the irradiated, thickest part and
the sites of microplanar beam entrance. (b) Higher magniﬁcation of the rectangle in panel
artery containing leukocytes appeared unaffected (open arrow). In the non-irradiated zone,
showing the missing capillary plexus. Few microvessels with intact (closed arrowhead) or fr
beam entrance. (d and e) Ultra-thin sections of preserved microvessels in panel c (CAM8) re
endothelial cell membrane (arrows), and broken irregular endothelial remains with large ga
2011 [15].irradiation than the highly differentiated vasculature of adult
organisms.
Microbeam radiation preferentially affects tumor vasculature
Beyond the difference of microbeam effects on mature versus
immature vessels, a preferential effect on tumor vessels was also
described for different tumor types. The effect of MRT, with or
without drug combination, on the enhancement of the survival of
tumor bearing animals and on tumor growth control has been
extensively described [3,7e12,26e28].
Mammary carcinoma
The therapeutic potential of different doses (75 Gy or 150 Gy)
deposited by 50 mmwide microbeams or 500 mmwide minibeams
was tested on mouse mammary carcinomas (4T1), a moderately
hypoxic tumor, resistant to radiotherapy and with a propensity to
metastasize [27]. A peak entrance dose of 150 Gy administered in
arrays of 50 mm wide beams was the most effective in delaying
tumor growth. The 500 mm beams at 75 Gy were unable to alter
tumor growth compared to untreated tumors. The two other con-
ﬁgurations gave intermediate tumor growth control. Administra-
tion of adjuvant anginex therapy (a novel anti-angiogenic peptide)
to these different conditions of irradiation further increased the
tumor growth delay.
Quantiﬁcation of immunohistochemically stained endothelial
cells (CD31) indicated that vessel density was signiﬁcantly lower 14
days after irradiation in all treated groups in comparison to animalsthe non-irradiated, thinner part of the membrane (open arrow). Closed arrows indicate
e is shown. In the irradiated, thicker zone, the capillary plexus was destroyed. A small
the capillaries were preserved (arrowheads). (c) Closer view of the rectangle in panel f
agmented (open arrowhead) blood cells were detected. The closed arrow indicates the
vealed endothelial cytoplasmic vacuolization (d, closed arrowheads), disrupted luminal
ps in between (e, closed arrowheads). Er ¼ erythrocyte. Adapted from Sabatasso et al.
A. Bouchet et al. / Physica Medica 31 (2015) 634e641638in the untreated group [27]. The number of pericytes, stained by an
anti-smooth muscle antibody (aSMA; smooth muscle pericyte-
associated blood vessels) signiﬁcantly increased in the irradiated
groups on day 14 after irradiation and seemed to correspond to a
vascular normalization. Grifﬁn and his colleagues proposed that
this effect might be exploited to improve tumor control using
agents targeting angiogenesis. A normalization of tumor vessels
after MRT seems to be in opposition with the destruction of
immature vessels observed on CAM and different tumor models. It
is difﬁcult to interpret and compare these results of normalization
with the others studies of vascularization because of the markedly
different conditions for the experiments. For example the different
doses (Grifﬁn et al. 2012: 75 or 150 Gy for 50micronwide beamlets,
200 micron on center distance; Bouchet et al. 2010: 2  400 Gy, 50
micron wide beamlets spaced at 200 micron on center) may have
played an important role also for MRT, as single doses of 5e10 Gy
(SRS/SBRT) cause relatively mild vascular damage, whereas higher
doses result in severe vascular damage and reduced blood perfu-
sion [29]. Also, the publication of Grifﬁn et al. excepted, there are
extremely few published data available on the presence or absence
of pericytes around remaining vessels of experimental tumors, and
on their inﬂuence on endothelial cells at the moment of irradiation.
Further, the tumor vasculatures are as diverse as are the different
tumor types and may thus react to radiation in many different
modes.
In tumors treated with minibeams delivering 75 Gy, the pres-
ence of areas reactive for pimonidazole, a marker of hypoxia, did
not differ from the mean pimonidazole staining intensity in control
tumors [27]. Conversely, tumors treated with microbeams (150 Gy)
revealed a substantial reduction of overall pimonidazole staining
intensity 1e14 days after MRT. The authors interpreted this dimi-
nution as an evidence of a decrease in tumor hypoxia after exposure
to 150 Gy (MRT). However, only a limited number of tumors have
been analyzed and statistical analysis concerning the effect of
hypoxia is lacking. We need also keep in mind that pimonidazole,
injected intravenously, might not have been delivered to unper-
fused tissue areas after the MRT. This may potentially be the reason
for the false negative results.
Administration of the adjuvant Anginex further exacerbated the
vascular modiﬁcations induced by MRT in all combination treat-
ment groups and illustrated the potential of an antiangiogenic
therapy coupled with MRT.
Brain tumors
MRT efﬁciently slows down the intracranial 9L gliosarcoma
growth in rats (Fig. 4A and B). In addition, an in vivo MR imaging
follow-up has demonstrated a signiﬁcant decrease in the fractional
blood volume in the tumor, and in diameter of tumor vessels, withFigure 4. Effects of MRT on rats bearing an orthotopic 9GLS tumor. Brain tumor growth co
evolution of the lesion size: untreated (aec), or treated by MRT (deh). B- Kaplan Meier curv
in grey, while animals treated by MRT are plotted in black. MRT induced a signiﬁcant increacross-ﬁred arrays beginning at 8 days after MRT [26]. Simulta-
neously, a striking remodeling of the tumor vasculature was
detected histologically, as evidenced by a decreased density of tu-
mor vessels with increased inter-vessel distances and endothelial
denudation [26,30] (Fig. 5AeC). These changes were associated
with a signiﬁcant decrease of the local tissue saturation with oxy-
gen, monitored by magnetic resonance based measurement
(MR_SO2) and with an histologic over-expression of an indirect
marker of hypoxia (GLUT1) in tumor tissue [30] (Fig. 5DeF). Taken
together, these results indicated that MRT-induced tumor vessel
damage led to a reduction of tumor oxygenation a few days after
MRT. Normal blood vessels were damaged only in peritumoral
brain tissue areas irradiated by both intersecting arrays. Thus,
during the subacute phase (6 weeks post MRT), brain edema and
overexpression of vascular endothelial growth factor were
observed in such areas subjected to cross-ﬁre beams. Conversely,
vascular parameters, vessel morphology and oxygenation were not
or only slightly modiﬁed in normal brain regions exposed to one of
the two MRT arrays. As reviewed above, vasculature of the normal
brain exposed to MRT remained sufﬁciently perfused to prevent
hypoxia in the normal brain. These data showed for the ﬁrst time
that MRT preferentially damages tumor vessels, but does not
impair normal brain blood vessels in a rat bearing an intracerebral
9L gliosarcoma.
The bloodebrain barrier permeability (as indicated by contrast
MR enhancement, Fig. 6) did not change in normal brain tissues
after MRT crossed by one or two directions of microbeam arrays
[26]. Conversely, MRT led to an increase in tumor vessel perme-
ability 2 and 5 days after irradiation, when the MR signal
enhancement reached 23.9 and 26.6%, respectively, whereas in
non-irradiated tumors the enhancement was only 16.6 and 20.3%
(p < 0.001). Thus, compared to the intrinsic permeability of un-
treated tumor vessels, the tumor vessel permeability was higher on
day 2 and day 5 after irradiation, by 44 and 31%, respectively. This
transient breakdown of the tumoreblood barrier might be used to
deliver intravenously injected drugs to the tumor core, thus
enhancing drug supply and therapeutic efﬁciency [26]. From the
ﬁfth to the ﬁfteenth day after irradiation the blood vessel perme-
ability of irradiated tumors decreased by 74%, (p < 0.001). We
interpret this as an impaired supply of contrast agent to the tumor
which correlates with the signiﬁcant decrease in tumor blood
volume and in number of tumor vessels that we observed at the
same delays after MRT (Fig. 5B, C).
MRT versus broad beam irradiation
There are several probable reasons why MRT gives a higher
therapeutic index for tumors than broad beam irradiation. Micro-
beams produce steep dose gradients between tissue slices receivingntrol and increase in rat survival. A- T2-weighted MR imaging follow-up illustrates the
es showing the survival of 9LGS tumor bearing rats. Untreated controls are represented
se in the median survival time of animals (D65 versus D20, log rank test, p ¼ 0.0003).
Figure 5. Effects of MRT on the vasculature of the brain and of the orthotopic 9GLS tumor. Tumor Blood volume, vessel density and endothelial denudation. A- Confocal images of
unirradiated and MRT-irradiated 9LGS tumor blood vessels. Type-IV collagen (red) and rat endothelial cell antigen (RECA-1; green) immunolabeling observed in irradiated (MRT þ)
and untreated control tumors (MRT -) at D12 and 18 after implantation i.e. 8 days after MRT treatment. Irradiated tumor vessels do not exhibit RECA-1 labeling 8 days after
treatment. Scale bar: 70 mm. B- Blood volume fraction values measured by MR imaging in the tumor, in the contralateral and ispsilateral hemispheres at different times after tumor
inoculation and MRT-treatment (mean ± SD). C- Mean number (±SEM) of vessels (positive for RECA-1/Type-IV collagen) per ﬁeld of view (FOV) measured in normal contralateral
hemispheres and tumoral tissues (9LGS) of unirradiated (black bars) rats or rats exposed to MRT (white bars). Tumor oxygenation and hypoxia marker. D- Merge of RECA-1 (red),
Type-IV Collagen (blue) and GLUT-1 (green) immunolabeling observed in tissue section of untreated (MRT-) or MRT-treated (MRTþ) 9GLS tumors 8 days after irradiation. Scale bar:
200 mm. E- MR measurement of oxygen saturation (MR_SO2) evolution in MRT treated and sham contralateral tissues and 9GLS tumors at different delays after tumor inoculation.
MRT was performed 10 days after implantation. *p < 0.01, **p < 0.001, two way ANOVA Bonferroni post-tests. F- Percentage of the indirect hypoxia marker GLUT-1 positive areas
measured in 9GLS tumors of both unirradiated rats (black bars) and rats exposed to MRT (white bars). Adapted from Bouchet et al., 2010 and Bouchet et al., 2013 [26,30]. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
A. Bouchet et al. / Physica Medica 31 (2015) 634e641 639the peak and valley doses: they have a 90%e10% dose fall-off, about
200 times steeper than that of a Gamma Knife. The radiotoxic dose
is therefore conﬁned to a very narrow zone while the integrity and
functionality of adjacent normal tissue in the valleys between theFigure 6. Vessel permeability measurements, indicated as contrast MR signal
enhancement. High vessel permeability values measured by MR imaging in the
intracranial tumor (9GLS), versus those noted in normal parts of the contralateral and
ispsilateral brain hemispheres, at different times after tumor inoculation and MRT
(mean ± SD). Adapted from Bouchet et al. 2010 [26].peaks is barely damaged. Further, spatial fractionation results in a
large speciﬁc contact surface between peak and valley zones, much
larger than that provided by a single broad beam [31]. This
extended contact surface is instrumental for the repair of heavily
irradiated tissues in peak regions by much less damaged tissues in
the valleys.
The important role of the high tolerance of the normal micro-
vasculature and arteries to irradiation by microbeams and the tu-
mor vasculature of 9LGS, for instance, has been described here;
they may result in tumor hypoxia and shrinkage. Conversely,
normal brain tissues exposed to microbeams remain sufﬁciently
perfused and maintain normoxia. Irradiation of normal rat brains
with microbeams is known to elicit proteomic responses that are
indicative of oncogenesis as well as in proteomic changes associ-
ated with bystander effects, indicative of apoptosis mediated by
reactive oxygen species. The acid-sphingomyelase mediated
endothelial apoptosis suggested after radiation-induced DNA
damage might be relevant in case of MRT as well [32]. Further,
potentially anti-oncogenic apoptotic proteomic changes indicate
that the collective interaction of such MB irradiation-induced
bystander effect proteins might confer a protective effect on
normal tissues [33].
A. Bouchet et al. / Physica Medica 31 (2015) 634e641640Transcriptional gene expression analysis of intracerebral glio-
sarcomas in rats revealed that MRT induced a response speciﬁc of
tumor tissue in comparison to normal tissue [34]. The speciﬁc
response of the tumor tissues is composed by 316 signiﬁcantly
modulated transcripts which are mainly related to immune/in-
ﬂammatory response, as described in a previous study [35]. But
there are other early biological processes underlying the differential
effect of MRT on tumor and normal brain [34]. Among the genes
isolated, 30werenot detectedbymicroarray in normal brain tissues,
neither before nor after MRT. Polo-like kinase 1 (Plk1) and some
associated genes (as Ccnb1, Cdc20, Pttg1), known to be necessary for
efﬁcient cell division and proposed as potential therapeutic target in
human tumors [36], showed a decreased expression after MRT. A
cluster of 20 genes presented a similar evolution of expression
during the ﬁrst days/weeks after MRT and their inhibition suggests
that a massive disorganization of cell division takes place. In addi-
tion, a progressive numerical increase in giant/polyploid cells and in
the proportion of polyploid cells among mitotic cells beginning 2
days afterMRTmight be associatedwithmitotic cell death. This is in
agreement with an early cytotoxic effect on tumor cells previously
described for the same tumor model [26,37].
On the contrary Areg, thought to be involved in tumor escape
and radioresistance [38], was signiﬁcantly overexpressed in 9L
gliosarcoma after MRT. This gene is an activator of the epidermal
growth factor receptor (EGFR) resulting in processes that are critical
for tumor survival and progression, involving tumor cell prolifer-
ation, invasiveness, motility, angiogenesis and inhibition of
apoptosis. These potential effects point to Areg/Amphiregulin as
potential target for increasing the therapeutic index of MRT. The
up-regulation of Areg expression may indicate the emergence of
survival processes in tumor cells triggered by the irradiation; while
the modulation of the “Plk1 cluster genes”, which relates to cyto-
kinetic features of the tumor observed histologically afterMRT, may
partially explain the control of tumor growth byMRT. A comparison
of the 9L brain tumor response after MRT or after synchrotron
broad beam irradiation is currently under analysis. However, in an
other model, Sprung et al. have identiﬁed MRT-induced immunity
related modulations in EM6.5 breast tumors in mice that were
clearly different from transcriptional changes induced by unseg-
mented broad beam X-rays [39].
Discussion and perspectives
Since the beginning and during the development of irradiation
using synchrotron-generated X-ray microbeams, the hypothesis
has emerged that the sparing of normal tissues was due to the
resistance of normal blood vessels to microbeam irradiation,
whereas immature tumor vessels cannot repair damage induced by
MRT. Over the past decades, different techniques and approaches
have tested and now lend support to this hypothesis. While no
major modiﬁcation was observed in normal vasculature [17,18,26],
tumors showed a denudation of the tumor vascular endothelium, a
decrease in number of vessels [26,27,30] leading to a decrease in
perfusion [26] and to tumor hypoxia [30]. On the contrary, in
another model study [27] the tumor vasculature presented signs of
normalization of the vasculature (i.e. presence of pericytes) along
with an improvement in the tumor oxygenation. However, these
phenomena were studied in only a few tumor models. The conse-
quences of tumor vessels modiﬁcations appear sometimes to be
contradictory, in particular for changes in tumor oxygenation as
observed in a brain and amammary tumor [27,30]. Complementary
studies with new approaches, such as in vivo stereotaxic micro-
scopy, testing different tumor models, as well as larger animals
such as pigs or pet animals are necessary for a better comprehen-
sion of vascular responses to MRT in normal tissues and tumors.Although microbeam radiation preferentially affects tumor
vessels in many ways, it would be simplistic to restrict the effects of
MRT to vascular effects alone. In the light of recent studies other
mechanisms seem to participate in the effectiveness of MRT. The
mode of action of microbeams, as of any radiation therapy, should
be considered as the sum of multi-level interactions of a complex
nature. Indeed, cytotoxic effects on tumor cells have been observed
[9], even before vascular parameters appeared to be modiﬁed [26],
and the redistribution of the cell cycle in the tumor was shown to
have occurred only a few hours after MRT [34]. MRT may also
induce transcriptomic changes such as an overexpression of the
resistance factor Areg which is critical for tumor survival and pro-
gression, as it involves tumor cell proliferation, invasiveness,
motility, inhibition of apoptosis and angiogenesis [40]. Moreover, a
strong involvement of immune and/or inﬂammatory responses
after MRT has been revealed in several recent studies [34,35,39].
MRT effects on vasculature, tumor cell proliferation arrest and
death, involvement of resistance mechanisms and immune
response can all be studied separately but an integrated consider-
ation of these mechanisms is now needed to understand the efﬁ-
ciency of MRT and to further increase the therapeutic potential of
this promising method.Acknowledgments
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